Go Pro
→ CODE RED: AI Meltdown Imminent? (From Paradigm Press) (Ad)tc pixel Free BPTH Stock Alerts

Bio-Path (BPTH) Competitors

Bio-Path logo
$0.0002 0.00 (-60.00%)
As of 10:57 AM Eastern
Compare

BPTH vs. SYRS, NAVB, GNCA, PXMD, and ARDS

Should you buy Bio-Path stock or one of its competitors? Bio-Path's main competitors and comparable companies include Syros Pharmaceuticals (SYRS), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), PaxMedica (PXMD), and Aridis Pharmaceuticals (ARDS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Bio-Path compare to Syros Pharmaceuticals?

Bio-Path (NASDAQ:BPTH) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Bio-Path has higher earnings, but lower revenue than Syros Pharmaceuticals. Bio-Path is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08M-$1.09N/A
Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bio-Path has a beta of -0.53, indicating that its share price is 153% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Bio-Path Neutral
Syros Pharmaceuticals Neutral

Bio-Path's return on equity of -2,842.40% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
Syros Pharmaceuticals N/A -3,369.56%-97.04%

Summary

Syros Pharmaceuticals beats Bio-Path on 6 of the 9 factors compared between the two stocks.

How does Bio-Path compare to Navidea Biopharmaceuticals?

Bio-Path (NASDAQ:BPTH) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Navidea Biopharmaceuticals has higher revenue and earnings than Bio-Path. Bio-Path is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08M-$1.09N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Bio-Path Neutral
Navidea Biopharmaceuticals Neutral

Navidea Biopharmaceuticals' return on equity of 0.00% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
Navidea Biopharmaceuticals N/A N/A N/A

Bio-Path has a beta of -0.53, indicating that its share price is 153% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats Bio-Path on 7 of the 9 factors compared between the two stocks.

How does Bio-Path compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Genocea Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.53, suggesting that its share price is 153% less volatile than the broader market.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Bio-Path Neutral

Bio-Path has lower revenue, but higher earnings than Genocea Biosciences. Bio-Path is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Bio-PathN/AN/A-$16.08M-$1.09N/A

Genocea Biosciences' return on equity of -182.88% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Bio-Path N/A -2,842.40%-337.48%

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 0.7% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Genocea Biosciences beats Bio-Path on 6 of the 9 factors compared between the two stocks.

How does Bio-Path compare to PaxMedica?

Bio-Path (NASDAQ:BPTH) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Bio-Path's return on equity of -2,842.40% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
PaxMedica N/A -3,167.89%-560.35%

5.7% of Bio-Path shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 0.7% of Bio-Path shares are held by insiders. Comparatively, 1.0% of PaxMedica shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bio-Path has a beta of -0.53, meaning that its stock price is 153% less volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market.

Bio-Path is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08M-$1.09N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Bio-Path Neutral
PaxMedica Neutral

Summary

Bio-Path beats PaxMedica on 6 of the 8 factors compared between the two stocks.

How does Bio-Path compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Aridis Pharmaceuticals' return on equity of 0.00% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Bio-Path N/A -2,842.40%-337.48%

Aridis Pharmaceuticals has a beta of 49.95, indicating that its stock price is 4,895% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.53, indicating that its stock price is 153% less volatile than the broader market.

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bio-Path is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00
Bio-PathN/AN/A-$16.08M-$1.09N/A

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Bio-Path Neutral

Summary

Aridis Pharmaceuticals beats Bio-Path on 7 of the 8 factors compared between the two stocks.

Get Bio-Path News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

BPTH vs. The Competition

Export
MetricBio-PathPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$11K$12.53B$7.26B$13.10B
Dividend YieldN/A2.63%2.52%12.57%
P/E Ratio0.00792.39274.9825.77
Price / SalesN/A850.84679.2597.61
Price / CashN/A88.6477.8052.76
Price / Book0.0010.6910.526.34
Net Income-$16.08M$2.83B$3.49B$360.00M
7 Day PerformanceN/A-0.69%-1.08%-0.11%
1 Month PerformanceN/A-1.10%-3.39%-3.42%
1 Year PerformanceN/A2.10%15.08%5.46%

Bio-Path Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPTH
Bio-Path
N/A$0.00
-60.0%		N/A-99.2%$11KN/AN/A10
SYRS
Syros Pharmaceuticals
N/A$0.00
flat		N/A+300.0%$11K$386KN/A120
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
PXMD
PaxMedica
N/A$0.00
flat		N/AN/A$6KN/AN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BPTH) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
NASA's ISS Replacement Could Go to This Tiny Space Firm
NASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
AI Panic: Sell now or wait?
Bank of America, Goldman Sachs, and Morgan Stanley have reportedly warned private clients about a coming stock...
TradeSmith | Sponsoredtc pixel